SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) today announced that Neurocrine
Biosciences management will present at the following investor
conferences:
- Matt Abernethy, Chief Financial
Officer, will present at the Credit Suisse 28th Annual
Healthcare Conference at 1:50 p.m. Mountain
Time (3:50 p.m. Eastern Time)
on Tuesday, Nov. 12, 2019, in
Scottsdale, Arizona.
- Kevin Gorman, Chief Executive
Officer, will present at the Jefferies London Healthcare Conference
at 10:00 a.m. Greenwich Mean Time
(5:00 a.m. Eastern Time) on
Wednesday, Nov. 20, 2019, in
London.
The live presentations will be webcast and may be accessed on
the Company's website under Investors at www.neurocrine.com. A
replay of the presentations will be available on the website
approximately one hour after the conclusion of the event and will
be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences
(Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company
with more than 25 years of experience discovering and developing
life-changing treatments for people with serious, challenging and
under-addressed neurological, endocrine and psychiatric disorders.
The company's diverse portfolio includes FDA-approved treatments
for tardive dyskinesia and endometriosis* and clinical development
programs in multiple therapeutic areas including Parkinson's
disease, congenital adrenal hyperplasia, uterine fibroids* and
polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes
in targeting and interrupting disease-causing mechanisms involving
the interconnected pathways of the nervous and endocrine systems.
For more information, visit neurocrine.com, and
follow the company on LinkedIn. (*in
collaboration with AbbVie)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-300952011.html
SOURCE Neurocrine Biosciences, Inc.